Evidence map›Paper›PMID 33502118›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2021

Cancer-on-a-Chip for Modeling Immune Checkpoint Inhibitor and Tumor Interactions.

Xing Jiang, Li Ren, Peyton Tebon, Canran Wang, Xingwu Zhou, Moyuan Qu, Jixiang Zhu, Haonan Ling, Shiming Zhang, Yumeng Xue and 11 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Genetic and phenotypic profiling of single living circulating tumor cells from patients with microfluidics.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  13. Review
  14. Review
  15. Review
  16. Organ-on-a-chip models for development of cancer immunotherapies.Cancer immunology, immunotherapy : CII · 2023
    Review
  17. Modeling immunity in microphysiological systems.Experimental biology and medicine (Maywood, N.J.) · 2023
    Review
  18. Review
  19. Review
  20. The Applications and Challenges of the Development ofCellular and molecular bioengineering · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 3 countries.

Xing JiangDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Li RenDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Peyton TebonDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Canran WangDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Xingwu ZhouDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Moyuan QuDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Jixiang ZhuDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Haonan LingDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Shiming ZhangDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Yumeng XueDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Qingzhi WuDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Praveen BandaruDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Junmin LeeDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Han-Jun KimDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Samad AhadianDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Nureddin AshammakhiDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Mehmet R DokmeciDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Jinhui WuState Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University & School of Life Sciences, Nanjing University, Nanjing, 210093, China.
Zhen GuDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Wujin SunDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Ali KhademhosseiniDepartment of Bioengineering, Center for Minimally Invasive Therapeutics, California Nanosystems Instituste, University of California, Los Angeles, Los Angeles, CA, 90095, USA.ORCID 0000-0002-2692-1524
California NanoSystems Institute · USChina Pharmaceutical University · CNNanjing University of Chinese Medicine · CN

Funding

Engineering personalized micro-tumor ecosystemsU01CA214411 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI, SENGUPTA, SHILADITYA · 2017 to 2021
$3.5M
NCI NIH HHS U01 CA214411
6 · The paper itself

Abstract

Cancer immunotherapies, including immune checkpoint inhibitor (ICI)-based therapies, have revolutionized cancer treatment. However, patient response to ICIs is highly variable, necessitating the development of methods to quickly assess efficacy. In this study, an array of miniaturized bioreactors has been developed to model tumor-immune interactions. This immunotherapeutic high-throughput observation chamber (iHOC) is designed to test the effect of anti-PD-1 antibodies on cancer spheroid (MDA-MB-231, PD-L1+) and T cell (Jurkat) interactions. This system facilitates facile monitoring of T cell inhibition and reactivation using metrics such as tumor infiltration and interleukin-2 (IL-2) secretion. Status of the tumor-immune interactions can be easily captured within the iHOC by measuring IL-2 concentration using a micropillar array where sensitive, quantitative detection is allowed after antibody coating on the surface of array. The iHOC is a platform that can be used to model and monitor cancer-immune interactions in response to immunotherapy in a high-throughput manner.

Indexed as

Immune Checkpoint InhibitorsNeoplasmsHumansImmunotherapyLab-On-A-Chip DevicesImmune Checkpoint Inhibitorscancer immunotherapycancer-on-a-chipdrug screeninghigh-throughput observation chamberimmune checkpoint inhibitors

Identifiers

PMID33502118
PMCPMC7939119
OpenAlexW3125509761

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.